Depression in Primary care: Interpersonal Counseling vs Selective serotonin reuptake inhibitors. The DEPICS Study. A multicenter randomized controlled trial. Rationale and design

Menchetti, Marco; Bortolotti, Biancamaria; Rucci, Paola; Scocco, Paolo; Bombi, Annarosa; Berardi, Domenico
January 2010
BMC Psychiatry;2010, Vol. 10, p97
Academic Journal
Background: Depression is a frequently observed and disabling condition in primary care, mainly treated by Primary Care Physicians with antidepressant drugs. Psychological interventions are recommended as first-line treatment by the most authoritative international guidelines but few evidences are available on their efficacy and effectiveness for mild depression. Methods/Design: This multi-center randomized controlled trial was conducted in 9 Italian centres with the aim to compare the efficacy of Inter-Personal Counseling, a brief structured psychological intervention, to that of Selective Serotonin Reuptake Inhibitors. Patients with depressive symptoms referred by Primary Care Physicians to psychiatric consultation-liaison services were eligible for the study if they met the DSM-IV criteria for major depression, had a score ≥13 on the 21-item Hamilton Depression Rating Scale, and were at their first or second depressive episode. The primary outcome was remission of depressive symptoms at 2-months, defined as a HDRS score ≤ 7. Secondary outcome measures were improvement in global functioning and recurrence of depressive symptoms at 12-months. Patients who did not respond to Inter-Personal Counseling or Selective Serotonin Reuptake Inhibitors at 2-months received augmentation with the other treatment. Discussion: This trial addresses some of the shortcomings of existing trials targeting major depression in primary care by evaluating the comparative efficacy of a brief psychological intervention that could be easily disseminated, by including a sample of patients with mild/moderate depression and by using different outcome measures. Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12608000479303


Related Articles

  • Effectiveness of Antidepressants Compared with Placebo for Depression in Primary Care. GUIRGUIS-BLAKE, JANELLE // American Family Physician;7/1/2010, Vol. 82 Issue 1, p42 

    The article compares the effectiveness and safety of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) with placebo for depression in primary care based on 14 randomized controlled trials of patients 18-65 years old. TCAs showed higher improvement in depression...

  • Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials. Deshauer, Dorian; Moher, David; Fergusson, Dean; Moher, Ester; Sampson, Margaret; Grimshaw, Jeremy // CMAJ: Canadian Medical Association Journal;5/6/2008, Vol. 178 Issue 10, p1293 

    Background: Selective serotonin reuptake inhibitors are increasingly used in the long-term treatment of depression. Much of the supporting evidence about the effects of these drugs comes from discontinuation trials, a variant of randomized controlled trials whose design is problematic to...

  • A systematic review of Chinese randomized clinical trials of SSRI treatment of depression. Ying Zhang; Becker, Thomas; Yongchun Ma; Koesters, Markus // BMC Psychiatry;2014, Vol. 14 Issue 1, p196 

    Background Selective serotonin reuptake inhibitors (SSRIs) have become the most frequently used antidepressants in China in recent decades. This systematic review and meta-analysis examined the efficacy and tolerability of SSRIs in Chinese studies and the quality of Chinese randomized controlled...

  • The Pivotal Prescribers. Schreiber, Curtis // Pharmaceutical Executive;Jul2003, Vol. 23 Issue 7, p62 

    Reports on the role of primary care practitioners for prescribing medications in the U.S. Difference between primary care practices and specialty care; Use of selective serotonin reuptake inhibitors to treat depression; Emphasis on the restorted view of actual medical practice.

  • Review: Response to SSRIs in unipolar depression occurs in the first week of treatment.  // Evidence Based Mental Health;Aug2007, Vol. 10 Issue 3, p81 

    The article presents a study which evaluates the effectiveness of selective serotonin reuptake inhibitors (SSRIs) in the treatment of patients with moderate to severe unipolar depression in Great Britain. Researchers conducted a systematic review with meta-analysis to randomized controlled...

  • Commentary. Kennedy, Sidney H. // Evidence Based Mental Health;Aug2007, Vol. 10 Issue 3, p81 

    The article comments on the study which evaluates the effectiveness of selective serotonin reuptake inhibitors in the treatment of moderate to severe unipolar depression. The author states that the strength of the said study is in the level of sophistication applied to the analyses. The author...

  • GENetic and clinical Predictors Of treatment response in Depression: the GenPod randomised trial protocol. Thomas, Laura; Mulligan, Jean; Mason, Victoria; Tallon, Debbie; Wiles, Nicola; Cowen, Philip; Nutt, David; O'Donovan, Michael; Sharp, Deborah; Peters, Tim; Lewis, Glyn // Trials;2008, Vol. 9, Special section p1 

    Background: The most effective pharmacological treatments for depression inhibit the transporters that reuptake serotonin (Selective Serotonin Reuptake Inhibitors -- SSRIs) and noradrenaline (Noradrenaline Reuptake Inhibitors -- NaRIs) into the presynaptic terminal. There is evidence to suggest...

  • Paroxetine and venlafaxine XR are effective in treating depression in patients with Parkinson's disease.  // Australian Journal of Pharmacy;Sep2012, Vol. 93 Issue 1108, p94 

    The article focuses on a study related to analyze the effectiveness and safety of various types of drugs including selective serotonin reuptake inhibitor and norepinephrine reuptake inhibitor for treating depression in patients with Parkinson's disease. Results after randomized trials indicating...

  • Vilazodone: A Review in Major Depressive Disorder in Adults. McCormack, Paul // Drugs;Nov2015, Vol. 75 Issue 16, p1915 

    Vilazodone (Viibryd) exhibits the combined properties of a selective serotonin reuptake inhibitor (SSRI) and a serotonin 5-HT receptor partial agonist, and is approved in the US for the treatment of major depressive disorder (MDD) in adults. In four randomized, double-blind, clinical trials,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics